IO Biotech Announces First Quarter Results for 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Merck Sharp News
Page 71 - Merck Sharp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Sharp. Real-time updates on events, politics, business and more.
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial | Minimally Invasive Surgery | JAMA
This randomized trial assesses the effect of robot-assisted radical cystectomy vs open radical cystectomy on number of days patients were alive and out of the h
Source: jamanetwork.com
HRQOL Data Support First-Line Lenvatinib-Pembrolizumab in Advanced Renal Cell Carcinoma
Health-related quality of life outcomes in patients with RCC were similar or favorable with lenvatinib-pembrolizumab vs sunitinib.
European Organization For The Research Functional Assessment European Organization Cancer Quality Life Questionnaire Core Merck Sharp
Source: cancertherapyadvisor.com
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving
Source: finanznachrichten.de
Investegate |Evaxion Biotech Announcements | Evaxion Biotech: Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
Investegate announcements from Evaxion Biotech, Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
Source: investegate.co.uk
Alkermes plc: Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation - - Trial-in-Progress Posters From ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented
Source: finanznachrichten.de
GI Innovation's GI-101 selected for government-initiated drug development program
[Courtesy of GI Innovation]SEOUL -- GI-101, an immunotherapy agent being developed by South Koreas bio-venture company GI Innovation, has been selected for a government-initiated drug development program to receive financial support at clinical stages. GI Innovation said it would get up to
Soult Ukpyolsi South Korea United States United Kingdom Korea Drug Development Fund Severance Hospital
Source: ajudaily.com
Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin), the companys novel,...
Source: prnewswire.com
The Chronic Pulmonary Hypertension Market is Expected to Witness Growth at a CAGR of 28.14% During the Study Period (2019-32)
/PRNewswire/ -- DelveInsights Chronic Pulmonary Hypertension Market Insights report includes a comprehensive understanding of current treatment practices,...
United States United Kingdom Acceleron Pharma Altavant Sciences Actelion Pharmaceuticals Key Chronic Pulmonary Hypertension Companies
Source: prnewswire.com
DelveInsight Business Research, LLP: The Chronic Pulmonary Hypertension Market is Expected to Witness Growth at a CAGR of 28.14% During the Study Period (2019-32)
The Chronic Pulmonary Hypertension market size is anticipated to surge owing to extensive research and development activities of pharmaceutical companies, along with the launch of various multiple-stage
United States United Kingdom Shruti Thakur Laboratorios Sophia Vaxil Biotherapeutics Legochem Biosciences
Source: finanznachrichten.de